Denali Therapeutics

Denali Therapeutics

Yahoo Finance • 5 days ago

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority Review Voucher following FDA approval... Full story

Yahoo Finance • 7 days ago

Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer's Disease. The nomination comes after the company exercised its opt... Full story

Yahoo Finance • 22 days ago

Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos

We just covered the Jeff Bezos Stock Portfolio: Top 10 Stock Picks and Denali Therapeutics Inc. (NASDAQ:DNLI) ranks 10th on this list. Jeff Bezos established a strategic relationship with Denali Therapeutics Inc. (NASDAQ:DNLI) through his... Full story

Yahoo Finance • last month

Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers

The S&P 500 Index ($SPX) (SPY) today is up +0.50%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.63%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.73%.  June E-mini S&P futures (ESM26) are up +0.47%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • last month

Stocks Supported by US-Iran Peace Deal Optimism

The S&P 500 Index ($SPX) (SPY) today is up +0.54%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.70%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.53%.  June E-mini S&P futures (ESM26) are up +0.50%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • last month

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Denali Therapeutics Inc. The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of... Full story

Yahoo Finance • 2 months ago

Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights

In early May 2026, Takeda informed Denali Therapeutics that it would terminate their collaboration on developing and commercializing DNL593 for business reasons unrelated to the drug’s efficacy or safety, returning full control of the prog... Full story

Yahoo Finance • 2 months ago

Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best Japanese stocks to buy right now. On April 6, Denali Therapeutics said Takeda Pharmaceutical Company Limited (NYSE:TAK) is ending its collaboration on DNL 593.Is Takeda Ph... Full story

Yahoo Finance • 2 months ago

What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in

Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best biotech stocks with highest upside potential. On April 6, Denali Therapeutics Inc. (NASDAQ:DNLI) revealed that it has received notice from Takeda (NYSE: TAK) about the terminati... Full story

Yahoo Finance • 5 months ago

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness established in anticipation of April 5, 202... Full story

Yahoo Finance • 6 months ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and normalization of liver volume Most common... Full story

Yahoo Finance • 6 months ago

3 Biotech Stocks With Major 2026 Catalysts

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among investors rebounded sharply, powering a no... Full story

Yahoo Finance • 6 months ago

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $1... Full story

Yahoo Finance • 6 months ago

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain i... Full story

Yahoo Finance • 7 months ago

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future... Full story

Yahoo Finance • 7 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future... Full story

Yahoo Finance • 8 months ago

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry... Full story

Yahoo Finance • 8 months ago

Denali Therapeutics Announces Board and Executive Leadership Updates

Denali Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has bee... Full story

Yahoo Finance • 8 months ago

DNLI January 2026 Options Begin Trading

Investors in Denali Therapeutics Inc (Symbol: DNLI) saw new options begin trading today, for the January 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 72 days... Full story

Yahoo Finance • 8 months ago

First Week of June 2026 Options Trading For Denali Therapeutics (DNLI)

Investors in Denali Therapeutics Inc (Symbol: DNLI) saw new options become available this week, for the June 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 244... Full story